Enhancing the effect of 5-aminolevulinic acid based photodynamic therapy in human meningioma cells

Photodiagnosis and Photodynamic Therapy

Volumn 11, Issue 1, 2014, Pages 1-6

  Cornelius, Jan Frederick ^a   Slotty, Philipp Jörg ^a   El Khatib, Mustafa ^a   Giannakis, Alexander ^a   Senger, Brigitte ^a   Steiger, Hans Jakob ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

5 ALA; Cancer therapy; Cell culture; Meningioma model; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; CIPROFLOXACIN; PHOTOSENSITIZING AGENT;

ADJUVANT THERAPY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIODE LASER; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LETHALITY; MALIGNANT MENINGIOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR CELL LINE; WST-1 ASSAY; CELL SURVIVAL; DOSE RESPONSE; DRUG COMBINATION; MENINGEAL NEOPLASMS; MENINGIOMA; PHOTOCHEMOTHERAPY; PROCEDURES; TIME;

AMINOLEVULINIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TIME FACTORS;

EID: 84895921129     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2014.01.001     Document Type: Article

References (36)

1. Aghi M.K., Carter B.S., Cosgrove G.R., et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009, 64:56-60. [discussion 60].
2. Beck T.J., Kreth F.W., Beyer W., et al. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 2007, 39:386-393.
3. Buccoliero A.M., Castiglione F., Degl'Innocenti D.R., et al. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Neuropathology 2007, 27:36-42.
4. Chamberlain M.C., Barnholtz-Sloan J.S. Medical treatment of recurrent meningiomas. Expert Rev Neurother 2011, 11:1425-1432.
5. Chamberlain M.C., Glantz M.J. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 2008, 113:2146-2151.
6. De Rosa F.S., Lopez R.F., Thomazine J.A., Tedesco A.C., Lange N., Bentley M.V. In vitro metabolism of 5-ALA esters derivatives in hairless mice skin homogenate and in vivo PpIX accumulation studies. Pharm Res 2004, 21:2247-2252.
7. Engenhart-Cabillic R., Farhoud A., Sure U., et al. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol 2006, 182:641-646.
8. Hino H., Murayama Y., Nakanishi M., Inoue K., Nakajima M., Otsuji E. 5-Aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes of different wavelengths in a mouse model of peritoneally disseminated gastric cancer. J Surg Res 2013.
9. Hong X., Jiang F., Kalkanis S.N., et al. Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy. Lasers Med Sci 2009, 24:777-786.
10. Inoue K., Fukuhara H., Kurabayashi A., et al. Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. Cancer Sci 2013, 104:765-772.
11. Ishikawa T., Kajimoto Y., Sun W., et al. Role of Nrf2 in cancer photodynamic therapy: regulation of human ABC transporter ABCG2. J Pharm Sci 2013.
12. Ishikawa T., Nakagawa H., Hagiya Y., Nonoguchi N., Miyatake S., Kuroiwa T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Adv Pharm Sci 2010, 2010:587306.
13. Kammerer R., Buchner A., Palluch P., et al. Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PLoS ONE 2011, 6:e21834.
14. Kawazoe K., Isomoto H., Yamaguchi N., et al. Effects of photodynamic therapy for superficial esophageal squamous cell carcinoma in vivo and in vitro. Oncol Lett 2010, 1:877-882.
15. Kim D.G., Kim Ch.H., Chung H.T., et al. Gamma knife surgery of superficially located meningioma. J Neurosurg 2005, 102(Suppl):255-258.
16. Kollova A., Liscak R., Novotny J., Vladyka V., Simonova G., Janouskova L. Gamma Knife surgery for benign meningioma. J Neurosurg 2007, 107:325-336.
17. Li J.H., Chen Z.Q., Huang Z., et al. In vitro study of low intensity ultrasound combined with different doses of PDT: effects on C6 glioma cells. Oncol Lett 2013, 5:702-706.
18. Milker-Zabel S., Zabel-du Bois A., Huber P., Schlegel W., Debus J. Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 2007, 68:858-863.
19. Muller P.J., Wilson B.C. Photodynamic therapy of brain tumors-a work in progress. Lasers Surg Med 2006, 38:384-389.
20. Ohgari Y., Miyata Y., Chau T.T., Kitajima S., Adachi Y., Taketani S. Quinolone compounds enhance delta-aminolevulinic acid-induced accumulation of protoporphyrin IX and photosensitivity of tumour cells. J Biochem 2011, 149:153-160.
21. Ohgari Y., Nakayasu Y., Kitajima S., et al. Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. Biochem Pharmacol 2005, 71:42-49.
22. Piot B., Rousset N., Lenz P., et al. Enhancement of delta aminolevulinic acid-photodynamic therapy in vivo by decreasing tumor pH with glucose and amiloride. Laryngoscope 2001, 111:2205-2213.
23. Riemenschneider M.J., Perry A., Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006, 5:1045-1054.
24. Stepp H., Beck T., Pongratz T., et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 2007, 26:157-164.
25. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
26. Sun W., Kajimoto Y., Inoue H., Miyatake S., Ishikawa T., Kuroiwa T. Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells. Photodiagnosis Photodyn Ther 2013, 10:42-50.
27. Takahashi K., Hasegawa T., Ishii T., et al. Antitumor effect of combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res 2013, 33:2861-2866.
28. Tanaka K., Sato C., Maeda Y., et al. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 1989, 64:2243-2249.
29. Teng L., Nakada M., Zhao S.G., et al. Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 2011, 104:798-807.
30. Thompson A.M. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007, 35:566-577.
31. Tsai J.C., Hsiao Y.Y., Teng L.J., Chen C.T., Kao M.C. Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Lasers Surg Med 1999, 24:296-305.
32. Valdes P.A., Moses Z.B., Kim A., et al. Gadolinium- and 5-aminolevulinic acid-induced protoporphyrin IX levels in human gliomas: an ex vivo quantitative study to correlate protoporphyrin IX levels and blood-brain barrier breakdown. J Neuropathol Exp Neurol 2012, 71:806-813.
33. Valdes P.A., Samkoe K., O'Hara J.A., Roberts D.W., Paulsen K.D., Pogue B.W. Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol 2010, 86:471-475.
34. van Nieuwenhuizen D., Klein M., Stalpers L.J., Leenstra S., Heimans J.J., Reijneveld J.C. Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 2007, 84:271-278.
35. Whittle I.R., Smith C., Navoo P., Collie D. Meningiomas. Lancet 2004, 363:1535-1543.
36. Wiemels J., Wrensch M., Claus E.B. Epidemiology and etiology of meningioma. J Neurooncol 2010, 99:307-314.